Steven16
2023-03-09
新药啥时估计能批准上市?
Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":627248985,"tweetId":"627248985","gmtCreate":1678375143747,"gmtModify":1678375145413,"author":{"id":3433494838648625,"idStr":"3433494838648625","authorId":3433494838648625,"authorIdStr":"3433494838648625","name":"Steven16","avatar":"https://static.tigerbbs.com/60af47707be9d6bacdbeb4efb27ae9f5","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>新药啥时估计能批准上市?</p></body></html>","htmlText":"<html><head></head><body><p>新药啥时估计能批准上市?</p></body></html>","text":"新药啥时估计能批准上市?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/627248985","repostId":2317912071,"repostType":2,"repost":{"id":"2317912071","kind":"highlight","pubTimestamp":1678155949,"share":"https://www.laohu8.com/m/news/2317912071?lang=&edition=full","pubTime":"2023-03-07 10:25","market":"us","language":"en","title":"Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb","url":"https://stock-news.laohu8.com/highlight/detail?id=2317912071","media":"Seeking Alpha","summary":"Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the","content":"<html><head></head><body><p>Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will provide up to $130M in gross proceeds to Unicycive through a private placement, including initial upfront funding of $30M.</p><p><img src=\"https://static.tigerbbs.com/62a2bcdd1a2f8f9b59e98e4bebfa8481\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>The company remains on track to file a New Drug Application (NDA) for Renazorb marketing approval with the FDA in mid-year.</p><p>Proceeds from the offering will be used to support the Company’s NDA submission of Renazorb for the treatment of hyperphosphatemia in the U.S. and, if approved, for the commercial launch of Renazorb in the U.S.</p><p>The funding is being led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and is supported by existing investors Nantahala Capital Partners and Rosalind Advisors. Gaurav Aggarwal, M.D., Managing Director of Vivo Capital, will join the Unicycive Board of Directors.</p><p>Pursuant to the securities purchase agreement, the Company will issue to purchasers (i) $30M in shares of Series A Convertible Preferred Stock and (ii) three tranches of warrants exercisable for convertible preferred stock.</p><p>Shares of Series A Convertible Preferred Stock will be issued at a price of $1,000.00 per share.</p><p>In December 2022, Unicycive announced that the primary endpoint was met in its bioequivalence study comparing Renazorb to Fosrenol.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-07 10:25 GMT+8 <a href=https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","UNCY":"Unicycive Therapeutics, Inc."},"source_url":"https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2317912071","content_text":"Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will provide up to $130M in gross proceeds to Unicycive through a private placement, including initial upfront funding of $30M.The company remains on track to file a New Drug Application (NDA) for Renazorb marketing approval with the FDA in mid-year.Proceeds from the offering will be used to support the Company’s NDA submission of Renazorb for the treatment of hyperphosphatemia in the U.S. and, if approved, for the commercial launch of Renazorb in the U.S.The funding is being led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and is supported by existing investors Nantahala Capital Partners and Rosalind Advisors. Gaurav Aggarwal, M.D., Managing Director of Vivo Capital, will join the Unicycive Board of Directors.Pursuant to the securities purchase agreement, the Company will issue to purchasers (i) $30M in shares of Series A Convertible Preferred Stock and (ii) three tranches of warrants exercisable for convertible preferred stock.Shares of Series A Convertible Preferred Stock will be issued at a price of $1,000.00 per share.In December 2022, Unicycive announced that the primary endpoint was met in its bioequivalence study comparing Renazorb to Fosrenol.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1292,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/627248985"}
精彩评论